DeepMed Research

Radboud University Medical Center

🇳🇱Netherlands

Country: 🇳🇱Netherlands

Ownership: Private

Established: 1951-01-01

Employees: -

Market Cap: -

Website: http://www.radboudumc.nl

Clinical Trials

Evaluation Research of a National Accreditation and Improvement Programme for General Practice

Not Applicable

Completed

Conditions: Cardiovascular Disease

Interventions: Other: National programme for accreditation and improvement of GP

First Posted Date: 2008-11-14

Last Posted Date: 2013-07-09

Lead Sponsor: Radboud University Medical Center

Target Recruit Count: 1685

Registration Number: NCT00791362

Locations: 🇳🇱
23 Locations, Nijmegen, Netherlands

In Vivo Effects of C1-esterase Inhibitor on the Innate Immune Response During Human Endotoxemia

Not Applicable

Completed

Conditions: Endotoxemia
Inflammation
Multi Organ Dysfunction Syndrome

Interventions: Drug: C1-esterase inhibitor
Drug: Endotoxin administration

First Posted Date: 2008-11-05

Last Posted Date: 2011-04-22

Lead Sponsor: Radboud University Medical Center

Target Recruit Count: 20

Registration Number: NCT00785018

Locations: 🇳🇱
Radboud University Nijmegen Medical Centre, Nijmegen, Netherlands

Anti-inflammatory Effects of GTS-21 After LPS

Not Applicable

Completed

Conditions: Endotoxemia
Sepsis
Vagal Activity

Interventions: Drug: GTS-21, [3-(2,4-dimethoxybenzylidene)-anabaseine dihydrochloride]
Drug: Placebo

First Posted Date: 2008-10-31

Last Posted Date: 2010-11-05

Lead Sponsor: Radboud University Medical Center

Target Recruit Count: 12

Registration Number: NCT00783068

Locations: 🇳🇱
Radboud University Nijmegen Medical Centre, Nijmegen, GLD, Netherlands

Validation of FDG-PET Segmentation Tools for Tumor Delineation by Correlation of CT- and FDG-PET Volume Measurements With Histopathology of Nodal Metastases of Head and Neck Carcinomas.

Conditions: Head and Neck Cancer

Interventions: Other: CT-FDG/PET scan of the head-and-neck region

First Posted Date: 2008-10-31

Last Posted Date: 2008-10-31

Lead Sponsor: Radboud University Medical Center

Target Recruit Count: 15

Registration Number: NCT00782691

Locations: 🇳🇱
Radboud University Nijmegen Medical Centre, Nijmegen, Gelderland, Netherlands

Determinants of Insulin-induced Weight Gain in Type 2 Diabetes Mellitus

Conditions: Type 2 Diabetes Mellitus
Weight Gain

Interventions: Device: Sensewear Bodymedia armband

First Posted Date: 2008-10-29

Last Posted Date: 2011-07-12

Lead Sponsor: Radboud University Medical Center

Target Recruit Count: 75

Registration Number: NCT00781495

Locations: 🇳🇱
Radboud University Nijmegen Medical Centre, Nijmegen, Gelderland, Netherlands
🇳🇱
Jeroen Bosch Hospital, 's-Hertogenbosch, Brabant, Netherlands

Study to the Optimal Duration of Therapy With Oral Angiogenesis Inhibitors

Phase 4

Conditions: Renal Cell Carcinoma
Gastrointestinal Stromal Tumor

Interventions: Drug: usage oral angiogenesis inhibitor
Drug: stop oral angiogenesis inhibitor

First Posted Date: 2008-10-22

Last Posted Date: 2011-09-16

Lead Sponsor: Radboud University Medical Center

Target Recruit Count: 30

Registration Number: NCT00777504

Locations: 🇳🇱
University Medical Center Nijmegen st Radboud, Nijmegen, Gelderland, Netherlands

Capiri-sutent Phase-1 in Advanced Colo-rectal Cancer

Phase 1

Conditions: Colorectal Cancer

First Posted Date: 2008-10-22

Last Posted Date: 2012-02-03

Lead Sponsor: Radboud University Medical Center

Target Recruit Count: 32

Registration Number: NCT00777478

Locations: 🇳🇱
University Medical Center Nijmegen st Radboud, Nijmegen, Gelderland, Netherlands

TPF Induction With Concomitant Chemoradiation to Treat Patients With Head and Neck Cancer

Phase 2

Conditions: Head and Neck Cancer

Interventions: Radiation: conventional radiotherapy with 'high' dose cisplatin
Radiation: accelerated radiotherapy with 'low' dose cisplatin

First Posted Date: 2008-10-17

Last Posted Date: 2012-04-11

Lead Sponsor: Radboud University Medical Center

Target Recruit Count: 70

Registration Number: NCT00774319

Locations: 🇳🇱
Netherlands Cancer Institute, Amsterdam, Netherlands
🇳🇱
University Medical Center Nijmegen st Radboud, Nijmegen, Netherlands

Open-Label Extension of LOCKCYST Trial

Phase 2

Conditions: Polycystic Liver Disease
Hepatomegaly
Liver Diseases
Polycystic Kidney
Autosomal Dominant

Interventions: Drug: lanreotide

First Posted Date: 2008-10-15

Last Posted Date: 2008-11-13

Lead Sponsor: Radboud University Medical Center

Target Recruit Count: 54

Registration Number: NCT00771888

Locations: 🇧🇪
University Hospital Gasthuisberg, University of Leuven, Leuven, Belgium
🇳🇱
Radboud University Nijmegen Medical Center, Nijmegen, Netherlands

Persantin Preceding Elective PCI

Phase 4

Completed

Conditions: Coronary Heart Disease
Percutaneous Transluminal Coronary Angioplasty
Atherosclerosis

Interventions: Drug: placebo
Drug: dipyridamole

First Posted Date: 2008-10-07

Last Posted Date: 2015-10-30

Lead Sponsor: Radboud University Medical Center

Target Recruit Count: 30

Registration Number: NCT00767663

Locations: 🇳🇱
RUNMC, Nijmegen, Netherlands
🇳🇱
Canisius Wilhelmina Hospital, Nijmegen, Netherlands

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy